University of Paris-Sorbonne-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2023

  1. Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study

    Clinical Colorectal Cancer, Vol. 22, Núm. 1, pp. 100-110

2021

  1. First-In-Human Phase I Study of a Next-Generation, Oral, TGFb Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

    Clinical Cancer Research, Vol. 27, Núm. 24, pp. 6666-6676

2018

  1. CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC) - Trial in progress

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. v84

2017

  1. Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer

    Annals of Oncology, Vol. 28, pp. iii135-iii136

  2. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

    European Journal of Cancer, Vol. 82, pp. 16-24

2014

  1. Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma

    European Journal of Cancer, Vol. 50, Núm. 3, pp. 496-505

2013

  1. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: Quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

    The Lancet Oncology, Vol. 14, Núm. 3, pp. 236-243

2011

  1. A phase 3 trial of bevacizumab in ovarian cancer

    New England Journal of Medicine, Vol. 365, Núm. 26, pp. 2484-2496